• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [237 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2026 Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2025 NIHR Health Services and Delivery Research programme Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2024 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: plasma sC5b-9 assay]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: an overview of emergency department visits and hospitalizations among young people aged 6 to 25 for mental health and psychosocial issues in 2022–2023, compared to the pre-pandemic (2016–2020) and pandemic periods (2020–2022) of COVID-19]
2024 Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of molnupiravir (Lagevrio)]
2024 NIHR Health Technology Assessment programme Evidence of quality of life for hospitalised patients with COVID-19: a scoping review
2024 WorkSafeBC Guanfacine, micronized PEA, or amygdala and insula retraining programs as treatment for long COVID
2024 WorkSafeBC Causal association between IBS and COVID-19
2024 NIHR Health and Social Care Delivery Program Understanding and using experiences of social care to guide service improvements: translating a co-design approach from health to social care
2024 NIHR Health and Social Care Delivery Program The Resilience Hub approach for addressing mental health of health and social care workers during the COVID-19 pandemic: a mixed-methods evaluation
2024 NIHR Health Services and Delivery Research programme Health visiting in the UK in light of the COVID-19 pandemic experience: (RReHOPE) findings from a realist review
2024 NIHR Health and Social Care Delivery Program Current experience and future potential of facilitating access to digital NHS primary care services in England: the Di-Facto mixed-methods study
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024 National Institute for Health and Care Excellence (NICE) Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. NICE technology appraisal guidance 971
2024 WorkSafeBC Causal association on the development of trigeminal neuralgia post covid-19 vaccine
2024 NIHR Health and Social Care Delivery Program Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024 WorkSafeBC COVID-19 and perimyocarditis
2024 NIHR Health Services and Delivery Research programme A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023 Health Information and Quality Authority (HIQA) International review of the epidemiology of long COVID
2023 Health Information and Quality Authority (HIQA) Interventions to improve long COVID symptoms: a systematic review
2023 Agency for Healthcare Research and Quality (AHRQ) Use of telehealth during the COVID-19 era
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of healthcare services by people with confirmed SARS-CoV-2 infection and those with no documented evidence of infection]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023 WorkSafeBC Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023 WorkSafeBC Migraines and the (Moderna) COVID-19 vaccine
2023 WorkSafeBC Causal association between COVID-19 infection and irritable larynx syndrome
2023 WorkSafeBC Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023 NIHR Health Services and Delivery Research programme A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023 NIHR Health Technology Assessment programme Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
2023 Health Information and Quality Authority (HIQA) Overview of multiplex antigen near-patient tests for acute respiratory infections
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42]
2023 WorkSafeBC Myalgic encephalomyelitis/chronic fatigue syndrome associated with mRNA COVID-19 vaccination
2023 National Institute for Health and Care Excellence (NICE) Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. NICE technology appraisal guidance 878
2023 National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2022 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post COVID-19 – effective treatment and rehabilitation]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022 Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022 Health Information and Quality Authority (HIQA) High level review of configuration and reform of public health systems in selected countries
2022 Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022 Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotrovimab (COVID-19, without supplemental oxygen, increased risk of severe disease) - Benefit assessment according to §35a Social Code Book V]
2022 Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022 Health Information and Quality Authority (HIQA) Catalogue of institutions undertaking COVID-19 horizon scanning
2022 Health Information and Quality Authority (HIQA) Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022 Health Information and Quality Authority (HIQA) COVID-19 Evidence Synthesis: International review of guidance on the use of face masks to mitigate the spread of SARS-CoV-2 infection
2022 WorkSafeBC Clinical accuracy of rapid antigen tests for COVID-19
2022 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of convalescent plasma donor therapy in the treatment of COVID-19]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirmatrelvir/ritonavir (COVID-19) - Benefit assessment acc. to § 35a Social Code Book V]
2022 Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022 WorkSafeBC Tinnitus and the COVID-19 vaccine
2022 WorkSafeBC Convergence insufficiency and COVID-19 infection
2022 WorkSafeBC Lose-dose naltrexone as treatment for post-COVID conditions
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Achieving safe surgery after COVID-19 vaccination
2022 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Update: guidelines on the preoperative diagnostic workup for COVID-19
2022 Agency for Healthcare Research and Quality (AHRQ) Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022 Agency for Healthcare Research and Quality (AHRQ) Infection prevention and control for the emergency medical services and 911 workforce
2022 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2022 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Effectiveness of social distancing measures, in the context of the COVID-19]
2022 Health Information and Quality Authority (HIQA) International review of clinical guidelines and models of care for long COVID
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2021 Penn Medicine Center for Evidence-based Practice (CEP) Triaging COVID-19 in the emergency department
2021 European Network for Health Technology Assessment (EUnetHTA) Convalescent plasma therapy for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Camostat for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Nafamostat for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Solnatide for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Anakinra for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) APN01 for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Darunavir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Favipiravir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Interferon (IFN) and Novaferon (NOVA) for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Gimsilumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Canakinumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Casirivimab and imdevimab (REGN-COV2) for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Bamlanivimab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Baricitinib for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Molnupiravir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) High-dose vitamin D for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Mavrilimumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Ivermectin for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Aspirin for the treatment of COVID-19
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: mandatory vaccination
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: thrombotic adverse events with adenovirus vaccines
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: vaccination for women who are pregnant or lactating
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: management of vaccine-associated thrombotic syndromes